Addus HomeCare Corporation (NASDAQ:ADUS – Get Free Report) EVP Cliff Donald Blessing sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $124.18, for a total transaction of $248,360.00. Following the completion of the sale, the executive vice president directly owned 10,183 shares of the company’s stock, valued at $1,264,524.94. The trade was a 16.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Addus HomeCare Price Performance
NASDAQ ADUS opened at $126.29 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.64 and a current ratio of 1.64. The firm’s 50 day moving average price is $117.97 and its 200-day moving average price is $107.02. Addus HomeCare Corporation has a 52-week low of $87.95 and a 52-week high of $131.59. The company has a market cap of $2.35 billion, a PE ratio of 21.05, a P/E/G ratio of 1.62 and a beta of 0.75.
Addus HomeCare (NASDAQ:ADUS – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The company had revenue of $387.74 million for the quarter, compared to analyst estimates of $388.72 million. Addus HomeCare had a net margin of 7.39% and a return on equity of 10.22%. Addus HomeCare’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company posted $1.56 earnings per share. Sell-side analysts forecast that Addus HomeCare Corporation will post 6.36 EPS for the current fiscal year.
Key Stories Impacting Addus HomeCare
- Neutral Sentiment: Addus said it will participate in the 2026 Stephens Annual Investment Conference. The announcement provides an opportunity to meet investors but gives no new financial or operating guidance. Article: Addus HomeCare to Participate in 2026 Stephens Annual Investment Conference
- Neutral Sentiment: A report listed short interest at zero shares, indicating no reported short position; however, its description of a “large increase” conflicts with that figure.
- Negative Sentiment: Several executives disclosed stock sales. CEO R. Allison sold 98,958 shares for about $12.2 million, reducing his holding by 35.08%. Five EVPs collectively sold 32,697 shares for roughly $4.1 million. Insider sales can weigh on sentiment, although they do not by themselves establish a negative outlook. CEO sale filing EVP sale filing EVP sale filing EVP sale filing EVP sale filing EVP sale filing
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of ADUS. BlackRock Inc. bought a new position in shares of Addus HomeCare during the 2nd quarter worth approximately $344,153,000. Dimensional Fund Advisors LP boosted its stake in Addus HomeCare by 11.8% in the first quarter. Dimensional Fund Advisors LP now owns 744,127 shares of the company’s stock valued at $69,689,000 after acquiring an additional 78,415 shares in the last quarter. Bank of America Corp DE acquired a new stake in Addus HomeCare in the second quarter valued at approximately $35,527,000. TimesSquare Capital Management LLC acquired a new stake in Addus HomeCare in the second quarter valued at approximately $31,502,000. Finally, Boston Partners boosted its stake in Addus HomeCare by 18.0% in the third quarter. Boston Partners now owns 290,332 shares of the company’s stock valued at $32,222,000 after acquiring an additional 44,279 shares in the last quarter. Institutional investors own 95.35% of the company’s stock.
Analyst Ratings Changes
ADUS has been the topic of several recent research reports. Raymond James Financial set a $137.00 target price on Addus HomeCare in a research report on Monday, September 28th. Truist Financial boosted their price target on Addus HomeCare from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. TD Cowen upped their price objective on Addus HomeCare from $131.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Royal Bank Of Canada upped their price objective on Addus HomeCare from $130.00 to $134.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Finally, UBS Group raised their price objective on Addus HomeCare from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Addus HomeCare presently has an average rating of “Moderate Buy” and a consensus price target of $134.70.
Addus HomeCare Company Profile
Addus HomeCare Corporation provides home-based care services to older adults and people with disabilities. Its services are designed to help clients receive care at home and in other community-based settings. The company operates through personal care, hospice and home health services. Personal care includes assistance with daily activities; hospice provides end-of-life care and support; and home health offers skilled nursing and therapy services. Founded in 1979, Addus serves communities across multiple states.
Featured Stories
- Five stocks we like better than Addus HomeCare
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.
